McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Andrew Williams is quoted extensively in a January 6, 2016 online edition of BioPharma in an article entitled, “US biosimilars in 2016: Where we’re at following Zarxio’s breakthrough.” The coming year could see a spate of biosimilar approvals in the US following Sandoz’s success in 2015, according to an IP lawyer, but questions surrounding FDA’s requirements still remain. View the article
